Table 2.
% Reduction of Edema and Inflammation Following Exposure to CEES or TPA.*
Class 1 (Bifunctionals) | Class 2 (Simple Esters) | Class 3 (AChEI Conjugates) | ||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Cmpd # | % Red. (CEES) | % Red. (TPA) | Cmpd # | % Red. (CEES) | % Red. (TPA) | Cmpd # | % Red. (CEES) | % Red. (TPA) |
1 | 20 | 41** | 9 | −35 | 6 | 20 | 60** | 80*** |
2 | 68 | 17 | 11 | 38 | 73*** | 22 | 76*** | 57** |
4 | 45 | 70** | 12 | NA | 94** | 24 | 75** | nd |
5 | 91** | 21** | 13 | 60** | 111*** | 27 | 86** | nd |
6 | 62 | 73*** | 15 | NA | 76** | |||
|
||||||||
7 | 90** | 24 | 16 | 38 | 47*** | NSAID Standards | ||
|
||||||||
8 | 24 | 31** | 18 | 113** | 29** | Diclofenac | 17 | 58*** |
Indomethacin | 46** | 55** | ||||||
Ibuprofen | −15 | −33 | ||||||
Naproxen | NS | 104** |
NS – reduction not statistically significant; nd – not determined; NA – not active.
Value differs from positive control based on one-way ANOVA, with P < 0.05.
Value differs from positive control based on one-way ANOVA, with P < 0.005.